Label: Information for the User
Tracrium 10 mg/ml Injectable Solution and for Infusion
Atracurium besilate
Read the entire label carefully before starting to use the medication,because it contains important information for you.
Tracrium belongs to a group of medications known as muscle relaxants.
It is used to relax muscles in numerous surgical operations, as well as in Intensive Care Units. It may also be used to facilitate the insertion of a tube into the trachea, if mechanical assistance with breathing is required.
No use Tracrium
Warnings and precautions
Consult your doctor if you or a family member has had any adverse reaction to an anesthetic (e.g. an unexpectedly long action), or if you or a family member has a warning card indicating that this has occurred in the past.
During the administration of Tracrium, there is a possibility of histamine release (a substance involved in allergies) in susceptible patients. Caution should be exercised when administering Tracrium to patients with a history suggesting increased sensitivity to histamine effects.
Before starting treatment with Tracrium, inform your doctor if you have or have had:
Inform your doctor:
Use of Tracrium with other medications
Inform your doctor or pharmacist if you are using or have recently used other medications, including those purchased without a prescription.
Tracrium may interact with other medications. It is essential to inform your doctor before receiving this medication if you know you are taking any of the following medications (consult your doctor if you have doubts):
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication.
Driving and operating machinery
It may be hazardous to drive or operate machinery immediately after surgery. Your doctor will tell you how long you should wait before driving and using machinery
Tracrium should only be administered in carefully controlled conditions under the supervision of an experienced and familiarized doctor with the use and action of muscle relaxants.
Your doctor will decide on the dose and duration of Tracrium treatment that they consider suitable for your operation.
Use in children
The use of Tracrium in children under 1 month of age is not recommended.
The dose of Tracrium is established based on body weight expressed in kilograms, the amount and duration of muscle relaxation desired, the expected response of the patient to the medication, and the method of administration of the drug. During muscle relaxation, your doctor will monitor neuromuscular function (nerves and muscles) to confirm that the dose you are receiving is correct.
If you use more Tracrium than you should
The effects of Tracrium are carefully controlled throughout the entire surgical intervention, and in the unlikely event that you are administered too much medication, the necessary corrective actions should be taken immediately.
Like all medications,Tracriummay cause side effects, although not everyone will experience them.
The side effects that may appear during or after the operation are as follows (those marked with the symbol # are attributed to histamine release):
Frequent side effects(may affect between 1 and 10 of every 100 people)
Infrequent side effects(may affect between 1 and 10 of every 1,000 people)
If these side effects appear, they will not last long and will be controlled by your doctor during the procedure.
Rare side effects(may affect between 1 and 10 of every 10,000 people)
Very rare side effects(may affect up to 1 of every 10,000 people)
Side effects of unknown frequency
If you consider that any of the side effects you experience are severe or if you notice any side effect not mentioned in this leaflet, inform your doctor or pharmacist.
Reporting side effects
If you experienceany type of side effect, consult your doctor or pharmacist, even if it is apossibleside effect not listed in this leaflet.You can also report them directly through theSpanish System for Pharmacovigilance of Medicinal Products for Human Use:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep out of sight and reach of children.
Store in refrigerator (between 2°C and 8°C). Do not freeze.
Store in original packaging to protect from light.
Any remaining Tracrium in opened vials must be discarded.
Do not use this medication after the expiration date shown on the packaging. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of packaging and unused medications. This will help protect the environment.
Aspect of the product and content of the packaging
Tracrium is an injectable solution that is presented in ampoules of 2.5 ml or 5 ml.
Each package contains 5 ampoules.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
Aspen Pharma Trading Limited
3016 Lake Drive,
Citywest Business Campus,
Dublin 24, Ireland
Tel: +34 952 010 137
Responsible for manufacturing
Industriestrasse 32-36,
23843 Bad Oldesloe,
Germany
Or
GlaxoSmithKline ManufacturingS.p.A.
Strada Provinciale Asolana, 90
43056 San Polo di Torrile (Parma)
Italy
Or
Aspen Pharma Ireland Limited
3016 Lake Drive, Citywest Business Campus
Dublin 24, Ireland
Local representative:
ASPEN PHARMACARE ESPAÑA, S.L.
Avenida Diagonal, 512,
Planta Interior 1, Office 4,
Barcelona, 08006, Spain
This information is intended solely for doctors or healthcare professionals:
Tracrium is compatible with the following infusion solutions for the periods below:
Infusion solution | Stability period |
Intravenous infusion(i.v.)of sodium chlorideBritish Pharmacopoeia (BP) (0.9% w/v) | 24 hours |
Infusioni.v.of glucose (5% w/v) BP | 8 hours |
Ringer's injectionUnited States Pharmacopeia (USP) | 8 hours |
Infusioni.v.of sodium chloride (0.18% w/v) and glucose (4% w/v) BP | 8 hours |
Infusioni.v.of sodium lactate BP (Hartmann's solution) | 4 hours |
When diluted in these infusion solutions to achieve concentrations of besylate of atracurium of 0.5 mg/ml and above, the resulting solutions will be stable at temperatures up to 25°C, under daylight, and for the established periods.
Last review date of this leaflet:September 2023
The detailed information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.